Dr Reddys Laboratories (RDY) Income from Discontinued Operations (2009 - 2019)
Dr Reddys Laboratories (RDY) posted quarterly Income from Discontinued Operations of 46000000.0 for Q2 2019, down 276.92% on a QoQ basis from 26000000.0 in Q1 2019.
Dr Reddys Laboratories (RDY) Income from Discontinued Operations (2009 - 2019) Analysis & Trends
Dr Reddys Laboratories (RDY) has reported Income from Discontinued Operations for 3 consecutive years, with 46000000.0 the latest figure, recorded in Q2 2019.
- Quarterly Income from Discontinued Operations changed N/A year-over-year to 46000000.0 in Q2 2019, while the trailing twelve-month figure through Jun 2019 was 2146000000.0 (changed N/A YoY) and the FY2019 annual result came in at 26000000.0, changed N/A from the prior year.
- Income from Discontinued Operations retreated to 46000000.0 in Q2 2019 per RDY's latest filing, from 26000000.0 in the prior quarter.
- Over the last five years, Income from Discontinued Operations for RDY reached as high as 26000000.0 in Q1 2019 and fell as low as 46000000.0 in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.46 Bn | 87.60 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.95 Bn | 32.21 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.69 Bn | 30.75 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.61 Bn | 23.55 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.21 Bn | 21.06 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.32 Bn | 18.51 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.84 Bn | 16.53 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Dr Reddys Laboratories | 9.83 Bn | 9.67 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | -46.00 Mn |
| Mar 31, 2019 | 26.00 Mn |
| Mar 31, 2010 | -973.00 Mn |
| Mar 31, 2009 | -1.15 Bn |